Immunosuppression in lung transplantation is an area devoid of robust clinical data. This chapter will review the history of immunosuppression in lung transplantation. Additionally, it will evaluate the three classes of induction, maintenance, and rescue immunosuppression in detail. Induction immunosuppression in lung transplantation aims to decrease incidence of lung allograft rejection, however infectious risk must be considered when determining if induction is appropriate and which agent is most favorable. Similar to other solid organ transplant patient populations, a multi-drug approach is commonly prescribed for maintenance immunosuppression to minimize single agent drug toxicities. Emphasis of this review is placed on key medication considerations including dosing, adverse effects, and drug interactions. Clinical considerations will be reviewed per drug class given available literature. Finally, acute cellular, antibody mediated, and chronic rejection are reviewed.
CITATION STYLE
Nelson, J., Kincaide, E., Schulte, J., Hall, R., & Levine, D. J. (2022). Immunosuppression in Lung Transplantation. In Handbook of Experimental Pharmacology (Vol. 272, pp. 139–164). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/164_2021_548
Mendeley helps you to discover research relevant for your work.